Timothy J. Richmond - 28 Feb 2025 Form 4 Insider Report for AbbVie Inc. (ABBV)

Reporting relationship: EVP, CHIEF HR OFFICER
Issuer ticker: ABBV
Reported as of: 28 Feb 2025
Net transaction value: -$7,937,697
SEC form: 4
Accepted by SEC: 04 Mar 2025, 17:00:13 UTC
Prior SEC filing: 28 Feb 2025
Source filing: View source filing
Reporting owner signature: /s/ T.O. Odutayo, Attorney-in-Fact for Timothy J. Richmond

Key filing fact

Timothy J. Richmond filed Form 4 for AbbVie Inc. (ABBV) on 04 Mar 2025.

Key facts

This page summarizes Timothy J. Richmond's Form 4 filing for AbbVie Inc. (ABBV).
4 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 04 Mar 2025, 17:00.

Change

Previous filing in this sequence was filed on 28 Feb 2025.
Current net transaction value: -$7,937,697.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ABBV transaction

Common stock, $0.01 par value

Tax liability

Transaction value: $3,465,658
Shares: -16,904
Change %: -38%
Price: $205.02
Shares after: 27,380
Date: 28 Feb 2025
Ownership: Direct

ABBV transaction

Common stock, $0.01 par value

Sale

Transaction value: $1,191,035
Shares: -5,677
Change %: -21%
Price: $209.80
Shares after: 21,703
Date: 03 Mar 2025
Ownership: Direct
Footnotes: F1

ABBV transaction

Common stock, $0.01 par value

Sale

Transaction value: $3,154,212
Shares: -14,973
Change %: -69%
Price: $210.66
Shares after: 6,730
Date: 03 Mar 2025
Ownership: Direct
Footnotes: F2

ABBV transaction

Common stock, $0.01 par value

Sale

Transaction value: $126,792
Shares: -600
Change %: -8.9%
Price: $211.32
Shares after: 6,130
Date: 03 Mar 2025
Ownership: Direct
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 3 footnotes

Footnote F1

The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $209.16 to $210, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Footnote F2

The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $210.25 to $211.23, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Footnote F3

The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $211.3 to $211.4, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.